Neurologists – PharmaLive

Biogen Alzheimer’s drug hits roadblocks with some hospitals, insurers

Alzheimer’s disease, Centers for Medicare and Medicaid Services (CMS), Cleveland Clinic, Health Insurers, Hospitals, Medical Experts, Medicare, Mount Sinai, Neurologists, Therapeutics, U.S. Institute for Clinical and Economic Review (ICER)

Biogen Inc.’s Alzheimer’s drug, the first new treatment for the memory-robbing disease in nearly 20 years, hit new barriers on July 15 with some large hospitals declining to use Aduhelm and health insurers delaying a decision while awaiting coverage terms from Medicare.

July 15, 2021/by Reuters Health

FDA Approves Viltepso for Duchenne Muscular Dystrophy

Accelerated Approval, Approvals, Duchenne Muscular Dystophy (DMD), Dystrophin, Exon 53 Skipping Therapy, FDA, FDA/Regulatory, Infusions, Muscle Wasting Disorders, Neurologists, Therapeutics

The U.S. Food and Drug Administration granted accelerated approval for NS Pharma’s Viltepso (viltolarsen) injection for patients with Duchenne muscular dystrophy who are amenable to exon 53 skipping therapy.

August 14, 2020/by Andrew Humphreys

Roche-PTC Therapeutics’ oral spinal muscular atrophy drug wins FDA approval

Analysts, Approvals, Drug Pricing, Express Scripts Holding, FDA, FDA/Regulatory, Infants, Neurologists, Oral Therapy, Proteins, Shares, Spinal Muscular Atrophy (SMA), Therapeutics

The U.S. Food and Drug Administration approved an oral treatment from Roche Holding AG and PTC Therapeutics Inc. for spinal muscular atrophy in adults and children two months and above.

August 7, 2020/by Andrew Humphreys

Physician burnout takes a toll on U.S. patients

Burnout, Critical care doctors, Depression, Dermatologists, Doctors, Neurologists, Ophthalmologists, Pathologists, Physicians, Plastic surgeons, Surveys

Nearly two-thirds of U.S. doctors feel burned out, depressed, or both – and those feelings affect how they relate to patients, according to a survey conducted by Medscape.

January 17, 2018/by Reuters Health